South Korea
· Delayed Price · Currency is KRW D&D Pharmatech Statistics
Total Valuation
D&D Pharmatech has a market cap or net worth of KRW 926.18 billion. The enterprise value is 907.83 billion.
| Market Cap | 926.18B |
| Enterprise Value | 907.83B |
Important Dates
The last earnings date was Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
D&D Pharmatech has 10.71 million shares outstanding. The number of shares has increased by 14.95% in one year.
| Current Share Class | 10.71M |
| Shares Outstanding | 10.71M |
| Shares Change (YoY) | +14.95% |
| Shares Change (QoQ) | +0.48% |
| Owned by Insiders (%) | 20.89% |
| Owned by Institutions (%) | 7.53% |
| Float | 7.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 86.17 |
| PB Ratio | 14.66 |
| P/TBV Ratio | 30.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -27.53 |
| EV / Sales | 84.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -35.30 |
Financial Position
The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.14.
| Current Ratio | 3.54 |
| Quick Ratio | 3.16 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.33 |
| Interest Coverage | -46.75 |
Financial Efficiency
Return on equity (ROE) is -57.28% and return on invested capital (ROIC) is -26.90%.
| Return on Equity (ROE) | -57.28% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -26.90% |
| Return on Capital Employed (ROCE) | -36.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +222.76% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +222.76% |
| 50-Day Moving Average | 65,881.00 |
| 200-Day Moving Average | 49,922.25 |
| Relative Strength Index (RSI) | 61.21 |
| Average Volume (20 Days) | 399,629 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, D&D Pharmatech had revenue of KRW 10.75 billion and -32.98 billion in losses. Loss per share was -3,151.14.
| Revenue | 10.75B |
| Gross Profit | 10.73B |
| Operating Income | -29.07B |
| Pretax Income | -34.37B |
| Net Income | -32.98B |
| EBITDA | -23.53B |
| EBIT | -29.07B |
| Loss Per Share | -3,151.14 |
Balance Sheet
The company has 26.15 billion in cash and 8.54 billion in debt, giving a net cash position of 17.61 billion or 1,644.76 per share.
| Cash & Cash Equivalents | 26.15B |
| Total Debt | 8.54B |
| Net Cash | 17.61B |
| Net Cash Per Share | 1,644.76 |
| Equity (Book Value) | 63.18B |
| Book Value Per Share | 5,970.15 |
| Working Capital | 23.73B |
Cash Flow
In the last 12 months, operating cash flow was -25.32 billion and capital expenditures -397.18 million, giving a free cash flow of -25.72 billion.
| Operating Cash Flow | -25.32B |
| Capital Expenditures | -397.18M |
| Free Cash Flow | -25.72B |
| FCF Per Share | -2,401.68 |
Margins
| Gross Margin | 99.79% |
| Operating Margin | -270.44% |
| Pretax Margin | -319.80% |
| Profit Margin | n/a |
| EBITDA Margin | -218.97% |
| EBIT Margin | -270.44% |
| FCF Margin | n/a |
Dividends & Yields
D&D Pharmatech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.95% |
| Shareholder Yield | n/a |
| Earnings Yield | -3.56% |
| FCF Yield | -2.78% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
D&D Pharmatech has an Altman Z-Score of 4.58.
| Altman Z-Score | 4.58 |
| Piotroski F-Score | n/a |